About DeepCure
DeepCure is a company based in Boston (United States) founded in 2018 by Thrasyvoulos Thras Karydis, Joseph Jacobson, and Kfir Schreiber. DeepCure has raised $64.6 million across 2 funding rounds from investors including IAG Capital Partners, Morningside and TLV Partners. DeepCure offers products and services including DC-15442 and Inspired Chemistry™ Platform.
- Headquarter Boston, United States
- Founders Thrasyvoulos Thras Karydis, Joseph Jacobson, Kfir Schreiber
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Deepcure
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$64.6 M (USD)
in 2 rounds
-
Latest Funding Round
$24.6 M (USD), Series A
Apr 11, 2024
-
Investors
IAG Capital Partners
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DeepCure
DeepCure offers a comprehensive portfolio of products and services, including DC-15442 and Inspired Chemistry™ Platform.
This candidate is developed as an oral STAT6 inhibitor that has been shown to achieve 100% in vivo inhibition of pSTAT6 and comparable efficacy to other treatments in disease models.
This platform is employed for automated chemical synthesis and has been utilized to generate top-selling drugs and diverse analogs in the context of immune disease research.
Funding Insights of DeepCure
DeepCure has successfully raised a total of $64.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $24.6 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $24.6M
-
First Round
First Round
(08 Nov 2021)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series A - DeepCure | Valuation | IAG Capital Partners |
|
| Nov, 2021 | Amount | Series A - DeepCure | Valuation | Morningside |
Investors in DeepCure
DeepCure has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include IAG Capital Partners, Morningside and TLV Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are provided by IAG Capital Partners.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location | |
|
VC firm investing in early stage startups in Israel & the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by DeepCure
Financial Statements - DeepCure
Deepcure Comparisons
Competitors of DeepCure
Latest news on Deepcure
Frequently Asked Questions about DeepCure
DeepCure was founded in 2018 and raised its 1st funding round 3 years after it was founded.
DeepCure is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Kfir Schreiber is the current CEO of DeepCure. They have also founded this company.
DeepCure is a funded company, having raised a total of $64.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Nov 08, 2021.
DeepCure was founded in 2018 and is based in Boston, United States. Small molecule therapies for immune diseases are developed through an automated chemical synthesis platform. Preclinical and clinical-stage candidates are advanced in the pipeline to address autoimmune disorders and other immune-mediated conditions. Collaborations with leading researchers are maintained to support therapeutic development in the biotechnology sector.
DeepCure offers DC-15442 and Inspired Chemistry™ Platform.
DeepCure has 5 investors. Key investors include IAG Capital Partners, Morningside, TLV Partners, Sapir Venture Partners, and Benon Group.